Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole effects on nerve excitability biomarkers in treatment-naive ALS
NL-OMON56704Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of riluzole in amyotrophic lateral sclerosis (ALS) (3 cohorts), sponsored by University Medical Center Utrecht. Primary endpoint: Peripheral nerve excitability measures. Started Jun 2025; status: recruiting.
02
Drugs
riluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON56704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56704.